What's in Kissei Pharmaceutical Co., Ltd.'s pipeline?

Kissei Pharmaceutical Co., Ltd. has 17 drugs in our index: 2 marketed, 0 filed, 6 in Phase 3, 7 in Phase 2, 2 in Phase 1.

Which companies overlap with Kissei Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Allergan, Eli Lilly and Company, Bayer, Astellas Pharma Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kissei-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Kissei Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Kissei Pharmaceutical Co., Ltd. pipeline: 2 marketed, 0 filed, 6 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 7 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
KAD-1229	KAD-1229	marketed	Potassium channel opener	ATP-sensitive potassium channel (KATP)	Cardiovascular
KLH-2109	KLH-2109	marketed	Potassium channel opener	ATP-sensitive potassium channel	Cardiovascular
PA21	PA21	phase 3	SGLT2 inhibitor	SGLT2 (Sodium-glucose cotransporter 2)	Diabetes
MR13A9	MR13A9	phase 3	SGLT2 inhibitor	SGLT2 (Sodium-Glucose Cotransporter 2)	Diabetes
JR-131	JR-131	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
KPS-0373	KPS-0373	phase 3	SGLT2 inhibitor	SGLT2 (Sodium-Glucose Cotransporter 2)	Diabetes
KPS-0373, High dose	KPS-0373, High dose	phase 3	TRPV1 antagonist	TRPV1	Pain Management
KPS-0373, Low dose	KPS-0373, Low dose	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Diabetes · 5
Cardiovascular · 2
Oncology · 1
Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
Allergan · 3 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Bayer · 2 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
Eurofarma Laboratorios S.A. · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Guangdong Raynovent Biotech Co., Ltd · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Kissei Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Kissei Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kissei-pharmaceutical-co-ltd. Accessed 2026-05-16.